A PYMNTS Company

The EC’s Investigation into the Pharmaceutical Sector: Trouble Ahead at the IP/Competition Intersection?

BY | November 11, 2008

This article is part of a Chronicle. See more from this Chronicle David Hull, Nov 12, 2008 Efforts by innovative pharmaceutical companies to protect their markets against generic drugs have…

This article is part of a Chronicle. See more from this Chronicle

David Hull, Nov 12, 2008

Efforts by innovative pharmaceutical companies to protect their markets against generic drugs have generated a wide-ranging debate over how to achieve the proper balance between these companies legitimate interests in reaping the full rewards of their research and development (R&D) efforts and the public’s interest in having access to cheaper drugs. In Europe, this debate has largely centered on

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.210.99.209

Please verify email or join us to access premium content!